Recently a clinical study called "A novel stool-based SDC2 DNA methylation test is more robust than FIT and plasma CEA in detecting colorectal neoplasia in China" was published on American Journal of Translational Medicine. The study compared the detection performance of Colosafe®, FIT and plasma CEA. The result evidently revealed the value and advantage of Colosafe® in clinical application.
All samples used in this study were from Shanghai Songjiang District Central Hospital. The scientific evidence from the paper once again verified superior performance of Colosafe® in clinical practice. Colosafe® has been promoted nationwide in China. The clinical data throughout the past three years from top hospitals in varied regions has demonstrated its consistency and accuracy in clinical practice. It has become a major screening method for colorectal cancer. It is the first NMPA-approved stool DNA test kit for colorectal cancer in China and has been recommended in the “Expert Consensus on Early Screening Protocol for Colorectal Cancer in China (2019 in Shanghai)” as one of the first-line options in population screening of colorectal cancer in addition to aiding clinical diagnosis of the malignant disease.
Over the years, CreativeBio has been striving to create every authentic product with innovative research and rigorous testing. In October, 2020, a paper on the outcome of a clinical trial of Colosafe sponsored by CreativeBio was published on Clinical Epigenetics titled “Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study”. By far, Colosafe® is the only stool-based testing product in China with peer-reviewed clinical studies published in international top-tiered journals, demonstrating the company’s stringent and scientific approach in developing products for making a healthier world.
There is an old saying in Chinese that “a long road tests a horse's stamina”, meaning in our case, that time will reveal the quality of our product and the character of our company. Early screening of colorectal cancer in China is still a nascent industry. CreativeBio is a trailblazer constantly in actions to develop innovative and advanced products to ultimately realize its lofty goal of “Human Health, My Mission”.
1. Wang X, Xu P, Shen H, et al. A novel stool-based SDC2 DNA methylation test is more robust than FIT and plasma CEA in detecting colorectal neoplasia in China. Am J of Translational Medicine. 2021; 5(1):37-50.
2. Wang, J., Liu, S., Wang, H. et al. Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study. Clin Epigenetics 2020;12(1): 162. doi: 10.1186/s13148-020-00954-x.